HKSE · 2162.HK
Keymed Biosciences Inc.
HK$67.10+HK$0.20 (+0.3%)
Keymed Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.24% below the high.
Loading market information…
HKSE · 2496.HK · HKD
Stock price
Quote as of Oct 20, 2026, 01:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Wuhan YZY Biopharma Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 54.76% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Wuhan YZY Biopharma Co., Ltd. is a biotechnology enterprise specializing in the development of bispecific antibody-based treatments. Its therapeutic focus areas include various cancers, their associated complications, and age-related ophthalmic conditions. The company's extensive portfolio of drug candidates aims to address a wide range of diseases, such as malignant ascites, malignant pleural effusion, various solid tumors (including pancreatic cancer, hepatocellular carcinoma, other advanced solid tumors, and HER2-positive solid tumors), small cell lung cancer, and relapsed/refractory multiple myeloma. Additionally, they are advancing therapies for COVID-19 and several eye disorders like wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and other conditions characterized by abnormal blood vessel formation in the eye. The company, established in 2010, is headquartered in Wuhan, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$67.10+HK$0.20 (+0.3%)
Keymed Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 25.24% below the high.
HK$4.75+HK$0.14 (+2.93%)
Ocumension Therapeutics’s quoted price sits in the lower half of its reported 52-week range, 46.92% below the high.
HK$15.40+HK$0.07 (+0.46%)
Beijing Luzhu Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.68% below the high.
HK$4.00HK$0.00 (0.0%)
Jiangsu Recbio Technology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 44.06% below the high.
HK$2.72-HK$0.02 (-0.73%)
Deewin Tianxia Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 76.14% below the high.
HK$6.58+HK$0.01 (+0.08%)
Gala Technology Holding Limited’s quoted price sits in the upper half of its reported 52-week range, 11.15% below the high.
HK$3.40-HK$0.15 (-4.23%)
Beijing Biostar Pharms Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 35.24% below the high.
HK$0.69-HK$0.04 (-4.86%)
Cutia Therapeutics’s quoted price sits in the lower half of its reported 52-week range, 91.14% below the high.
